Zivo Bioscience Inc (ZIVO) - Net Assets
Based on the latest financial reports, Zivo Bioscience Inc (ZIVO) has net assets worth $-3.29 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($559.45K) and total liabilities ($3.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Zivo Bioscience Inc (ZIVO) total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.29 Million |
| % of Total Assets | -587.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Zivo Bioscience Inc - Net Assets Trend (2003–2024)
This chart illustrates how Zivo Bioscience Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Zivo Bioscience Inc for the complete picture of this company's asset base.
Annual Net Assets for Zivo Bioscience Inc (2003–2024)
The table below shows the annual net assets of Zivo Bioscience Inc from 2003 to 2024. For live valuation and market cap data, see Zivo Bioscience Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-514.90K | +76.66% |
| 2023-12-31 | $-2.21 Million | -20666.74% |
| 2022-12-31 | $-10.62K | -100.18% |
| 2021-12-31 | $6.04 Million | +153.42% |
| 2020-12-31 | $-11.31 Million | -35.64% |
| 2019-12-31 | $-8.34 Million | +62.58% |
| 2018-12-31 | $-22.28 Million | -36.66% |
| 2017-12-31 | $-16.30 Million | -19.70% |
| 2016-12-31 | $-13.62 Million | -43.43% |
| 2015-12-31 | $-9.50 Million | -49.11% |
| 2014-12-31 | $-6.37 Million | +33.61% |
| 2013-12-31 | $-9.59 Million | -142.50% |
| 2012-12-31 | $-3.96 Million | -94.74% |
| 2011-12-31 | $-2.03 Million | -113.46% |
| 2010-12-31 | $-951.68K | +74.86% |
| 2009-12-31 | $-3.79 Million | -628.57% |
| 2008-12-31 | $-519.60K | +31.21% |
| 2007-12-31 | $-755.37K | +9.27% |
| 2006-12-31 | $-832.54K | -41.09% |
| 2005-12-31 | $-590.09K | +46.48% |
| 2004-12-31 | $-1.10 Million | -2968.34% |
| 2003-12-31 | $-35.94K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zivo Bioscience Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13692220400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.62K | % |
| Other Components | $136.45 Million | % |
| Total Equity | $-514.90K | 100.00% |
Zivo Bioscience Inc Competitors by Market Cap
The table below lists competitors of Zivo Bioscience Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ata Gayrimenkul Yatirim Ortakligi AS
IS:ATAGY
|
$14.00 Million |
|
Tong Hua Holding Public Company Limited
BK:TH
|
$14.00 Million |
|
Maming Enam Sembilan Mineral Tbk PT
JK:AKSI
|
$14.01 Million |
|
Churchill Capital Corp IX Warrant
NASDAQ:CCIXW
|
$14.04 Million |
|
Waja Konsortium Bhd
KLSE:0102
|
$14.00 Million |
|
Huize Holding Ltd
NASDAQ:HUIZ
|
$13.99 Million |
|
Quantum BioPharma Ltd.
NASDAQ:QNTM
|
$13.99 Million |
|
Financiere Marjos SA
PA:FINM
|
$13.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zivo Bioscience Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -2,205,843 to -514,897, a change of 1,690,946.
- Net loss of 13,384,836 reduced equity.
- New share issuances of 5,602,269 increased equity.
- Other factors increased equity by 9,473,513.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.38 Million | -2599.52% |
| Share Issuances | $5.60 Million | +1088.04% |
| Other Changes | $9.47 Million | +1839.89% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Zivo Bioscience Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $-0.17 | $3.80 | x |
| 2003-12-31 | $-0.30 | $3.80 | x |
| 2004-12-31 | $-7.75 | $3.80 | x |
| 2005-12-31 | $-2.59 | $3.80 | x |
| 2006-12-31 | $-1.94 | $3.80 | x |
| 2007-12-31 | $-1.43 | $3.80 | x |
| 2008-12-31 | $-0.79 | $3.80 | x |
| 2009-12-31 | $-4.11 | $3.80 | x |
| 2010-12-31 | $-0.87 | $3.80 | x |
| 2011-12-31 | $-1.68 | $3.80 | x |
| 2012-12-31 | $-18.73 | $3.80 | x |
| 2013-12-31 | $-41.04 | $3.80 | x |
| 2014-12-31 | $-16.78 | $3.80 | x |
| 2015-12-31 | $-34.81 | $3.80 | x |
| 2016-12-31 | $-48.85 | $3.80 | x |
| 2017-12-31 | $-56.20 | $3.80 | x |
| 2018-12-31 | $-68.26 | $3.80 | x |
| 2019-12-31 | $-14.48 | $3.80 | x |
| 2020-12-31 | $-13.37 | $3.80 | x |
| 2021-12-31 | $4.75 | $3.80 | x |
| 2022-12-31 | $-0.01 | $3.80 | x |
| 2023-12-31 | $-1.31 | $3.80 | x |
| 2024-12-31 | $-0.15 | $3.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zivo Bioscience Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8513.44%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-6.76%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.45K |
| 2003 | 0.00% | -32191.49% | 0.17x | 0.00x | $-537.22K |
| 2004 | 0.00% | -7866.21% | 0.92x | 0.00x | $-3.75 Million |
| 2005 | 0.00% | -6207.23% | 0.15x | 0.00x | $-5.90 Million |
| 2006 | 0.00% | -1191.15% | 0.92x | 0.00x | $-3.46 Million |
| 2007 | 0.00% | -1395.18% | 0.59x | 0.00x | $-2.18 Million |
| 2008 | 0.00% | -1025.33% | 0.41x | 0.00x | $-1.76 Million |
| 2009 | 0.00% | -1790.32% | 0.20x | 0.00x | $-1.04 Million |
| 2010 | 0.00% | -8609.82% | 0.24x | 0.00x | $-7.03 Million |
| 2011 | 0.00% | -2629.30% | 0.22x | 0.00x | $-2.53 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.85 Million |
| 2013 | 0.00% | -3841.12% | 0.12x | 0.00x | $-9.14 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $1.32 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.84 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.70 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.41 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.41 Million |
| 2019 | 0.00% | -73339.91% | 0.05x | 0.00x | $-13.83 Million |
| 2020 | 0.00% | -48278.92% | 0.09x | 0.00x | $-8.52 Million |
| 2021 | -155.52% | 0.00% | 0.00x | 1.49x | $-10.00 Million |
| 2022 | 0.00% | -215933.16% | 0.00x | 0.00x | $-8.74 Million |
| 2023 | 0.00% | -28127.25% | 0.05x | 0.00x | $-7.56 Million |
| 2024 | 0.00% | -8513.44% | 0.10x | 0.00x | $-13.33 Million |
Industry Comparison
This section compares Zivo Bioscience Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zivo Bioscience Inc (ZIVO) | $-3.29 Million | 0.00% | N/A | $14.00 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Zivo Bioscience Inc
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically act… Read more